Cargando…

Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors

Selective cyclooxygenase-2 (COX-2) inhibitors were developed to reduce the gastrointestinal toxicity of conventional nonsteroidal anti-inflammatory agents. However, COX-2 inhibitors decrease prostacyclin production and may disrupt the normal homeostatic balance, leading to a prothrombotic state and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Debabrata, Topol, Eric J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC154429/ https://www.ncbi.nlm.nih.gov/pubmed/12716442 http://dx.doi.org/10.1186/ar609

Ejemplares similares

COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients
por: Hochberg, Marc C
Publicado: (2003)

Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair
por: Einhorn, Thomas A
Publicado: (2003)

COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease
por: Crofford, Leslie J
Publicado: (2003)

COX-2: Where are we in 2003? - Distinction from NSAIDs becoming blurred
por: Day, Richard
Publicado: (2003)

COX-2 and EGFR: Partners in Crime Split by Aspirin
por: Patrignani, Paola, et al.
Publicado: (2015)

Select Dietary Phytochemicals Function as Inhibitors of COX-1 but Not COX-2
por: Li, Haitao, et al.
Publicado: (2013)

Experimental status epilepticus, COX‐2 and BDNF: Connecting the dots
por: Marchi, Nicola
Publicado: (2021)

Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors
por: Moussa, Nathalie, et al.
Publicado: (2023)

COX-2 Inhibitors and Gastric Cancer
por: Wang, Zhen, et al.
Publicado: (2014)

Adverse Effects of COX-2 Inhibitors
por: Sharma, Jagdish N., et al.
Publicado: (2005)

Radiolabeled COX-2 Inhibitors for Non-Invasive Visualization of COX-2 Expression and Activity — A Critical Update
por: Laube, Markus, et al.
Publicado: (2013)

Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007)

Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
por: Borer, Jeffrey S, et al.
Publicado: (2005)

COX inhibitors and breast cancer
por: Mazhar, D, et al.
Publicado: (2006)

Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
por: Harris, Randall E, et al.
Publicado: (2012)

Anaphylaxis to selective COX-2 inhibitors: an unexpected culprit
por: Dias de Castro, Eunice, et al.
Publicado: (2015)

Seizure following the Use of the COX-2 Inhibitor Etoricoxib
por: Arnao, Valentina, et al.
Publicado: (2017)

Cox-2 inhibitors in mandibular third molar surgery
por: Janarthanan, K., et al.
Publicado: (2019)

Molecular docking analysis of COX-2 for potential inhibitors
por: Selvaraj, Jayaraman, et al.
Publicado: (2020)

Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs
por: Scheiman, James M, et al.
Publicado: (2005)

New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases
por: Chen, Wujun, et al.
Publicado: (2021)

The mitochondrial TMEM177 associates with COX20 during COX2 biogenesis
por: Lorenzi, Isotta, et al.
Publicado: (2018)

Binding Energy Calculation of Patchouli Alcohol Isomer Cyclooxygenase Complexes Suggested as COX-1/COX-2 Selective Inhibitor
por: Raharjo, Sentot Joko, et al.
Publicado: (2014)

Pharmacologic Inhibition of COX-1 and COX-2 in Influenza A Viral Infection in Mice
por: Carey, Michelle A., et al.
Publicado: (2010)

Viscum album-Mediated COX-2 Inhibition Implicates Destabilization of COX-2 mRNA
por: Saha, Chaitrali, et al.
Publicado: (2015)

Mechanical Thrombectomy- Where Do We Stand Now ?
por: Chakraborty, Debabrata, et al.
Publicado: (2022)

Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1/COX-2 inhibitors
por: Hussein, Abdel Haleem M., et al.
Publicado: (2020)

Cyclooxygenase (COX) Inhibitors and the Newborn Kidney
por: Smith, Francine G., et al.
Publicado: (2012)

Thiazoles and Thiazolidinones as COX/LOX Inhibitors
por: Liaras, Konstantinos, et al.
Publicado: (2018)

Colorectal Carcinoma, Cyclooxygenases, and COX Inhibitors
por: Ganduri, Vinutna, et al.
Publicado: (2022)

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors
por: Harris, Randall E, et al.
Publicado: (2006)

Differential usage of COX-1 and COX-2 in prostaglandin production by mast cells and basophils
por: Bando, Tomoyuki, et al.
Publicado: (2017)

Participation of COX-1 and COX-2 in the contractile effect of phenylephrine in prepubescent and old rats
por: Guevara-Balcazar, Gustavo, et al.
Publicado: (2017)

Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013)

Design, Synthesis, and Evaluation of New Tripeptides as COX-2 Inhibitors
por: Vernieri, Ermelinda, et al.
Publicado: (2013)

Design and Synthesis of Imidazopyrazolopyridines as Novel Selective COX-2 Inhibitors
por: Badrey, Mohamed G., et al.
Publicado: (2015)

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006)

The COX-2/PGE(2)/EP3/G(i/o)/cAMP/GSIS Pathway in the Islet: The Beat Goes On
por: Robertson, R. Paul
Publicado: (2017)

In Silico Analysis of the Potential of the Active Compounds Fucoidan and Alginate Derived from Sargassum Sp. as Inhibitors of COX-1 and COX-2
por: Dewi, Lestari
Publicado: (2016)

Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis
por: Zhu, Xi-Tian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c6529de5a1viqp4mpkvocnesm0